Dr. David Younger serves as the Chief Executive Officer and co-founder of A-Alpha Bio, a biotechnology startup spun out of the University of Washington's Institute for Protein Design. Having helped establish the company based on pioneering academic research into protein-protein interactions, he leads its overall strategic direction, technological development, and commercial partnerships. Under his executive guidance, the company utilizes its proprietary experimental platforms to measure and analyze massive arrays of protein interactions, supporting drug discovery efforts across diverse therapeutic application areas.